



# ESMO 2018 Congress

Munich, Germany  
October 19-23, 2018

<b>Session Type:</b>	Proffered Paper Session
<b>Session Title:</b>	<a href="#">Head and Neck Cancer</a>
<b>Presentation Number:</b>	1044O
<b>Presentation Date:</b>	Monday, October 22, 2018
<b>Presentation Time:</b>	2:45 p.m. – 3:00 p.m. CEST
<b>Presentation Title:</b>	A phase 1b/2 study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results